Stonebridge Capital Advisors’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $10.4M | Buy |
11,358
+403
| +4% | +$409K | 0.73% | 49 |
|
|
2025
Q4 | $11.8M | Buy |
10,955
+436
| +4% | +$417K | 0.82% | 42 |
|
|
2025
Q3 | $8.03M | Buy |
10,519
+8,003
| +318% | +$5.96M | 0.57% | 52 |
|
|
2025
Q2 | $1.96M | Buy |
2,516
+204
| +9% | +$159K | 0.15% | 88 |
|
|
2025
Q1 | $1.91M | Buy |
2,312
+420
| +22% | +$349K | 0.16% | 87 |
|
|
2024
Q4 | $1.46M | Sell |
1,892
-757
| -29% | -$627K | 0.12% | 99 |
|
|
2024
Q3 | $2.35M | Buy |
2,649
+19
| +0.7% | +$17.1K | 0.19% | 86 |
|
|
2024
Q2 | $2.38M | Sell |
2,630
-78
| -3% | -$62.4K | 0.21% | 82 |
|
|
2024
Q1 | $2.11M | Sell |
2,708
-118
| -4% | -$84K | 0.19% | 100 |
|
|
2023
Q4 | $1.65M | Buy |
2,826
+1,085
| +62% | +$633K | 0.17% | 102 |
|
|
2023
Q3 | $935K | Sell |
1,741
-82
| -4% | -$42.3K | 0.1% | 119 |
|
|
2023
Q2 | $855K | Sell |
1,823
-195
| -10% | -$81.8K | 0.09% | 121 |
|
|
2023
Q1 | $693K | Buy |
2,018
+52
| +3% | +$17.5K | 0.08% | 126 |
|
|
2022
Q4 | $719K | Sell |
1,966
-6
| -0.3% | -$2.13K | 0.09% | 125 |
|
|
2022
Q3 | $638K | Sell |
1,972
-35
| -2% | -$11.1K | 0.08% | 127 |
|
|
2022
Q2 | $651K | Sell |
2,007
-25
| -1% | -$7.5K | 0.08% | 128 |
|
|
2022
Q1 | $582K | Buy |
2,032
+135
| +7% | +$34.7K | 0.06% | 131 |
|
|
2021
Q4 | $524K | Buy |
1,897
+26
| +1% | +$6.59K | 0.06% | 135 |
|
|
2021
Q3 | $432K | Sell |
1,871
-1,555
| -45% | -$384K | 0.05% | 141 |
|
|
2021
Q2 | $722K | Buy |
3,426
+1,913
| +126% | +$384K | 0.05% | 149 |
|
|
2021
Q1 | $283K | Sell |
1,513
-200
| -12% | -$39.1K | 0.04% | 156 |
|
|
2020
Q4 | $289K | Buy |
1,713
+144
| +9% | +$21.5K | 0.04% | 150 |
|
|
2020
Q3 | $232K | Buy |
1,569
+27
| +2% | +$4.18K | 0.04% | 157 |
|
|
2020
Q2 | $253K | Sell |
1,542
-300
| -16% | -$46K | 0.05% | 147 |
|
|
2020
Q1 | $256K | Sell |
1,842
-44
| -2% | -$6.05K | 0.05% | 138 |
|
|
2019
Q4 | $248K | Buy |
1,886
+189
| +11% | +$21.9K | 0.04% | 165 |
|
|
2019
Q3 | $190K | Sell |
1,697
-75
| -4% | -$8.35K | 0.03% | 177 |
|
|
2019
Q2 | $196K | Sell |
1,772
-50
| -3% | -$5.89K | 0.03% | 178 |
|
|
2019
Q1 | $236K | Sell |
1,822
-114
| -6% | -$13.9K | 0.04% | 161 |
|
|
2018
Q4 | $224K | Sell |
1,936
-362
| -16% | -$40.4K | 0.05% | 142 |
|
|
2018
Q3 | $247K | Sell |
2,298
-50
| -2% | -$5K | 0.05% | 145 |
|
|
2018
Q2 | $201K | Buy |
+2,348
| New | +$193K | 0.04% | 159 |
|
|
2018
Q1 | – | Sell |
-2,373
| Closed | -$200K | – | 183 |
|
|
2017
Q4 | $200K | Buy |
+2,373
| New | +$202K | 0.05% | 161 |
|
Other funds holding LLY
VCM
VPM
Stonebridge Capital Advisors's LLY Position: Q1 2026 in Review
Stonebridge Capital Advisors increased its Eli Lilly (LLY) stake by 3.7% in Q1 2026, buying an estimated $409K and bringing the position to 11,358 shares worth $10.4M. The position accounts for 0.73% of the portfolio, ranked #49.
Stonebridge Capital Advisors first reported a position in LLY in Q4 2017 and has held it in 33 quarters since. The position peaked at $11.8M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Stonebridge Capital Advisors held 11,358 shares of Eli Lilly worth $10.4M as of Q1 2026.
- Stonebridge Capital Advisors bought 403 Eli Lilly shares in Q1 2026, an estimated $409K.
- Eli Lilly made up 0.73% of Stonebridge Capital Advisors's portfolio in Q1 2026, its #49 holding.
- Stonebridge Capital Advisors first reported a position in Eli Lilly in Q4 2017 and has held it in 33 quarters since.
- Stonebridge Capital Advisors's Eli Lilly position peaked at $11.8M in Q4 2025.
- 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Stonebridge Capital Advisors's 13F filing for Q1 2026, filed 14 May 2026.